D-methionine

Phase 3Small molecule

SSouthern Illinois University

D-methionine is one of 7 small molecule programs targeting Noise-Induced Hearing Loss. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Noise-Induced Hearing LossActive, not recruiting

Noise-Induced Hearing LossPhase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Noise-Induced Hearing Loss

#DrugCompanyPhaseTrials

Epsom Salt

FFresenius Kabi Oncology Ltd.

Approved

—2

Cysteine Hydrochloride

Novartis

Phase 2

1 3

Medrol

Pfizer

Phase 1

1 4

EPI-743

EEdison Pharmaceuticals Inc

Phase 2

1 5

Zonegran

AAzurity Pharmaceuticals

Phase 1

1 6

D-methionine

SSouthern Illinois University

Phase 3

1 7

Zinc Gluconate

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Noise-Induced Hearing Loss1 trial

Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)

Terminated·SSouthern Illinois University·Phase 3·NCT02903355·351 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for D-methionine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-methionine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-methionine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Southern Illinois University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSouthern Illinois University

D-methionine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Noise-Induced Hearing Loss1 trial

References

Drug Info

Quick Facts

Related News